Dave Nichols, MD is a professor of pediatrics at Seattle Children’s Hospital at the University of Washington and the medical director of the CF Therapeutics Development Network Coordinating Center (TDNCC). He has provided CF medical care for both adults and children with CF for several years and now helps to support and lead a number of CF clinical research trials. Dave currently co-leads the PROMISE and SIMPLIFY studies in the U.S., which are considering how using Trikafta affects the lives of those with CF, including how they feel after starting this medication and whether they continue to benefit from daily inhaled medications like dornase alfa and hypertonic saline.